Patrick Magill
Overview
Explore the profile of Patrick Magill including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
223
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Thongprasert S, Duffield E, Saijo N, Wu Y, Yang J, Chu D, et al.
J Thorac Oncol
. 2011 Oct;
6(11):1872-80.
PMID: 22011650
Introduction: Evaluation of health-related quality-of-life (HRQoL) and symptom improvement were preplanned secondary objectives for the overall population and posthoc analyses for epidermal growth factor receptor (EGFR) mutation-positive/negative subgroups in IPASS....
2.
Osborne C, Neven P, Dirix L, Mackey J, Robert J, Underhill C, et al.
Clin Cancer Res
. 2011 Jan;
17(5):1147-59.
PMID: 21220480
Purpose: Increased growth factor signaling may contribute to tamoxifen resistance. This randomized phase II trial assessed tamoxifen plus placebo or the epidermal growth factor receptor inhibitor gefitinib in estrogen receptor...
3.
Smith I, Walsh G, Skene A, Llombart A, Mayordomo J, Detre S, et al.
J Clin Oncol
. 2007 Aug;
25(25):3816-22.
PMID: 17679728
Purpose: Increased epidermal growth factor receptor (EGFR) expression may promote breast cancer resistance to endocrine therapy. We have therefore investigated whether neoadjuvant gefitinib, an EGFR inhibitor, might overcome biologic and...
4.
Kennedy S, Jin X, Yu H, Zhong S, Magill P, van Vliet T, et al.
Fertil Steril
. 2006 Jun;
86(3):762-4.
PMID: 16784743
A proof-of-concept study to assess the safety and efficacy of a traditional Chinese medicine formula as treatment for primary dysmenorrhea showed no statistically significant benefit over placebo. However, some efficacy...